CD274 and cancer: In doing so, we highlighted commonalities and differences of the interplay between affinity, blocking of the PD-1:PD-L1 interaction and regions recognized on PD-1 that contributed to the functional performance of the anti-PD-1 antibodies approved by regulatory agencies globally to treat cancer.